JP4320705B2 - Rhoキナーゼ阻害剤 - Google Patents
Rhoキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP4320705B2 JP4320705B2 JP2002576235A JP2002576235A JP4320705B2 JP 4320705 B2 JP4320705 B2 JP 4320705B2 JP 2002576235 A JP2002576235 A JP 2002576235A JP 2002576235 A JP2002576235 A JP 2002576235A JP 4320705 B2 JP4320705 B2 JP 4320705B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- rho kinase
- compounds
- cell
- rho
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Description
たラセミ形または光学活性形のどれも含む。
ここで以下の略号が使用される時、それらは以下の意味を持つ。
Ac2 O 無水酢酸
anhy 無水
n−BuOH n−ブタノール
t−BuOH t−ブタノール
CD3 OD メタノールーd4
Celite ケイ藻土濾過剤、Celite Corp.
CH2 Cl2 塩化メチレン
CI−MS 化学的イオン化質量スペクトル分析
conc 濃縮
dec 分解
DME ジメトキシエタン
DMF N,N−ジメチルホルムアミド
DMSO ジメチルスルホキシド
ELSD 蒸発光散乱検出器
EtOAc 酢酸エチル
EtOH エタノール(100%)
Et2 O ジエチルエーテル
Et3 N トリエチルアミン
HPLC ES−MS 高速液体クロマトグラフィー/エレクトロスプレー質量スペク トル分析
NMM 4−メチルモルホリン
Ph3 P トリフェニルフォスフィン
Pd(dppf)Cl2 〔1,1’−ビス(ジフェニルホスフィノ)フェロセン〕ジク ロロパラジウムII
Pd(PPh3 )4 テトラキス(トリフェニルホスフィン)パラジウム(O)
Pd(OAc)2 酢酸パラジウム
P(O)Cl3 オキシ塩化リン
Rf TLC保持係数
RT 保持時間(HPLC)
rt 室温
THF テトラヒドロフラン
TFA トリフロロ酢酸
TLC 薄層クロマトグラフィー
以下の一般的方法を記載するために使用した式中で、R1 およひR2 は水素もしくはメトキシであり、R3 はメトキシエチル、シクロプロピル、4−フロロフェニルもしくは4−ピリジルであり、本発明の化合物I−VIを製造するために適宜選択される。
2−N−5’−アミノインダゾール−4−クロロ−6,7−ジメトキシキナゾリン
N−〔2−(2,4−ジクロロフェニル)−4−キナゾリニル〕−N−(1H−インダゾール−5−イル)アミンの製造
N2−(4−フロロフェニル)−N4−(1H−インダゾール−5−イル)−6,7−ジメトキシ−2,4−キナゾリンジアミン
Claims (1)
- 下記式IないしVIのいずれかの化合物または薬剤的に許容し得るそれらの塩:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27797401P | 2001-03-23 | 2001-03-23 | |
US31533801P | 2001-08-29 | 2001-08-29 | |
PCT/US2002/008660 WO2002076977A2 (en) | 2001-03-23 | 2002-03-22 | Rho-kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004528314A JP2004528314A (ja) | 2004-09-16 |
JP4320705B2 true JP4320705B2 (ja) | 2009-08-26 |
Family
ID=26958818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002576235A Expired - Fee Related JP4320705B2 (ja) | 2001-03-23 | 2002-03-22 | Rhoキナーゼ阻害剤 |
Country Status (19)
Country | Link |
---|---|
US (3) | US20030087919A1 (ja) |
EP (1) | EP1370552B1 (ja) |
JP (1) | JP4320705B2 (ja) |
AR (1) | AR035792A1 (ja) |
AT (1) | ATE353889T1 (ja) |
AU (1) | AU2002245709A1 (ja) |
CA (1) | CA2441501C (ja) |
CY (1) | CY1108041T1 (ja) |
DE (1) | DE60218138T2 (ja) |
DK (1) | DK1370552T3 (ja) |
ES (1) | ES2280517T3 (ja) |
HK (1) | HK1061029A1 (ja) |
MX (1) | MXPA03008659A (ja) |
MY (1) | MY142915A (ja) |
PE (1) | PE20020958A1 (ja) |
PT (1) | PT1370552E (ja) |
TW (1) | TWI336328B (ja) |
UY (1) | UY27225A1 (ja) |
WO (1) | WO2002076977A2 (ja) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
ATE546143T1 (de) | 2002-08-29 | 2012-03-15 | Santen Pharmaceutical Co Ltd | Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen |
GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
EP1616577B1 (en) * | 2003-04-18 | 2011-09-21 | Senju Pharmaceutical Co., Ltd. | 2-chloro-6,7-dimethoxy-N-5 [5-(1)H- indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride for use in repairing corneal perception. |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
BR122016015715B8 (pt) | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico |
EP2468729B1 (en) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Novel indazole derivative |
EP1868579B1 (en) | 2005-03-07 | 2010-09-29 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
CN101253166B (zh) | 2005-08-30 | 2013-07-10 | 旭化成制药株式会社 | 磺酰胺化合物 |
TW200815398A (en) | 2006-06-08 | 2008-04-01 | Ube Industries | A novel indazole derivative having spirocyclic structure in the side chain |
CA2700988A1 (en) * | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
CN103641833A (zh) * | 2006-12-08 | 2014-03-19 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
EA019941B1 (ru) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
AU2008220104B2 (en) | 2007-02-28 | 2012-09-27 | Asahi Kasei Pharma Corporation | Sulfonamide derivative |
CN101730690B (zh) | 2007-07-02 | 2013-01-16 | 旭化成制药株式会社 | 磺酰胺化合物及其结晶 |
ES2659980T3 (es) | 2007-08-29 | 2018-03-20 | Senju Pharmaceutical Co., Ltd. | Agente para promover la adherencia de células endoteliales de la córnea |
WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
CN105861446B (zh) | 2009-10-16 | 2021-10-01 | 斯克里普斯研究所 | 多能细胞的诱导 |
EP4364797A2 (en) | 2009-10-19 | 2024-05-08 | FUJIFILM Cellular Dynamics, Inc. | Cardiomyocyte production |
EP2582794B2 (en) | 2010-06-15 | 2024-04-24 | FUJIFILM Cellular Dynamics, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
CN114164167A (zh) | 2010-12-22 | 2022-03-11 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
KR101940340B1 (ko) | 2011-03-04 | 2019-01-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 아미노-퀴놀린 |
DK2694644T3 (en) | 2011-03-30 | 2018-04-16 | Cellular Dynamics Int Inc | Priming of pluripotent stem cells for neural differentiation |
CA2841165A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
CA2858173C (en) | 2011-12-06 | 2023-09-26 | Advanced Cell Technology, Inc. | Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof |
EP2799537B1 (en) | 2011-12-28 | 2021-09-22 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
EP2628482A1 (en) | 2012-02-17 | 2013-08-21 | Academisch Medisch Centrum | Rho kinase inhiitors for use in the treatment of neuroblastoma |
EP2826855B1 (en) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
WO2013151186A1 (ja) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | エリスロポエチン産生細胞の誘導方法 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
KR20150118152A (ko) | 2013-02-21 | 2015-10-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 퀴나졸린 |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
JP6602288B2 (ja) | 2013-04-03 | 2019-11-06 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 浮遊液中で内胚葉前駆細胞を培養するための方法および組成物 |
CA2909230C (en) | 2013-04-12 | 2021-06-15 | Kyoto University | Method for inducing alveolar epithelial progenitor cells |
SG11201510201PA (en) | 2013-06-11 | 2016-01-28 | Univ Kyoto | Method for producing renal progenitor cells and drug comprising the same |
JP6548576B2 (ja) | 2013-07-30 | 2019-07-24 | 京都府公立大学法人 | 角膜内皮細胞マーカー |
EP3031905A4 (en) | 2013-08-07 | 2017-04-26 | Kyoto University | Method for producing pancreatic hormone-producing cell |
CN105849255A (zh) | 2013-09-05 | 2016-08-10 | 国立大学法人京都大学 | 新的产多巴胺神经前体细胞诱导方法 |
WO2015064768A1 (ja) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
BR112016011096A2 (pt) | 2013-11-27 | 2017-09-19 | Kyoto Prefectural Public Univ Corp | Aplicação de laminina à cultura de célula endotelial da córnea |
EP3604499A1 (en) | 2014-03-04 | 2020-02-05 | Fate Therapeutics, Inc. | Improved reprogramming methods and cell culture platforms |
WO2015178431A1 (ja) | 2014-05-21 | 2015-11-26 | 国立大学法人京都大学 | 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤 |
JP7253692B2 (ja) | 2014-12-26 | 2023-04-07 | 国立大学法人京都大学 | 肝細胞誘導方法 |
CA3001917A1 (en) | 2015-10-16 | 2017-04-20 | Fate Therapeutics, Inc. | Platform for the induction & maintenance of ground state pluripotency |
KR20180092951A (ko) | 2015-10-30 | 2018-08-20 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법 |
US20190083543A1 (en) | 2016-02-15 | 2019-03-21 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
WO2017150174A1 (ja) * | 2016-03-04 | 2017-09-08 | 株式会社シンスター・ジャパン | 2,4-ジアミノキナゾリン誘導体又はその塩を有効成分として含有する医薬品組成物、及び、特定の構造を有する2,4-ジアミノキナゾリン誘導体 |
EP3447130A4 (en) | 2016-04-22 | 2019-11-13 | Kyoto University | METHOD FOR PRODUCING DOPAMINE-PROPERING NEURAL PRESERVATOR CELLS |
EP4328301A2 (en) | 2016-08-16 | 2024-02-28 | FUJIFILM Cellular Dynamics, Inc. | Methods for differentiating pluripotent cells |
US11821007B2 (en) | 2017-05-25 | 2023-11-21 | Kyoto University | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
CN111566204B (zh) | 2017-11-10 | 2024-03-26 | 再生医科学股份有限公司 | 培养细胞的制造方法、脊髓损伤疾病的治疗剂的制造方法 |
CA3082643A1 (en) | 2017-11-14 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
CN111479568A (zh) | 2017-12-21 | 2020-07-31 | 参天制药株式会社 | 司培前列素与Rho激酶抑制剂的组合药物 |
CN111542598A (zh) | 2017-12-28 | 2020-08-14 | 株式会社钟化 | 多能干细胞聚集抑制剂 |
US20210062159A1 (en) | 2017-12-28 | 2021-03-04 | Kaneka Corporation | Cell aggregation promoter |
JP7257333B2 (ja) | 2017-12-28 | 2023-04-13 | 株式会社カネカ | 細胞凝集抑制剤 |
US20200405768A1 (en) | 2018-02-19 | 2020-12-31 | Sumitomo Dainippon Pharma Co., Ltd. | Cell Aggregate, Mixture of Cell Aggregates, and Method for Preparing Same |
US20210332329A1 (en) | 2018-07-23 | 2021-10-28 | Kyoto University | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
WO2020045642A1 (ja) | 2018-08-31 | 2020-03-05 | 学校法人同志社 | 眼細胞を保存または培養するための組成物および方法 |
WO2020071438A1 (ja) | 2018-10-02 | 2020-04-09 | 学校法人同志社 | 角膜内皮細胞を保存するための方法および容器 |
US20220056413A1 (en) | 2018-12-21 | 2022-02-24 | Kyoto University | Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
WO2020203538A1 (ja) | 2019-03-29 | 2020-10-08 | 株式会社カネカ | 多能性幹細胞を含む細胞集団及びその製造方法 |
JPWO2020230832A1 (ja) | 2019-05-15 | 2020-11-19 | ||
BR112022017180A2 (pt) | 2020-02-27 | 2022-10-18 | Kyoto Prefectural Public Univ Corp | Células endoteliais da córnea humanas funcionais e aplicação das mesmas |
JPWO2022149616A1 (ja) | 2021-01-08 | 2022-07-14 | ||
CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
KR20240005837A (ko) | 2021-05-03 | 2024-01-12 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 성숙한 각막 내피 세포의 생성 방법 |
EP4353243A1 (en) | 2021-06-10 | 2024-04-17 | Ajinomoto Co., Inc. | Method for producing mesenchymal stem cells |
JPWO2023017848A1 (ja) | 2021-08-11 | 2023-02-16 | ||
AU2022343749A1 (en) | 2021-09-13 | 2024-03-28 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
US5245038A (en) * | 1987-11-06 | 1993-09-14 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
DE69221175T2 (de) * | 1991-02-07 | 1998-01-15 | Roussel Uclaf | Bizyklische Stickstoffverbindungen, ihre Herstellung, erhaltene Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
MX9200299A (es) * | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
US5851545A (en) * | 1995-08-25 | 1998-12-22 | Sandoz Ltd. | Insecticidal matrix and process for preparation thereof |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
DE19608653A1 (de) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
WO1998002434A1 (en) * | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
DE69737631T3 (de) * | 1996-08-12 | 2011-08-18 | Mitsubishi Tanabe Pharma Corp. | MEDIKAMENTE ENTHALTEND Rho-KINASE INHIBITOREN |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
WO2000010981A1 (en) * | 1998-08-21 | 2000-03-02 | Parker Hughes Institute | Quinazoline derivatives |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
AU2096100A (en) * | 1998-12-23 | 2000-07-31 | Bayer Aktiengesellschaft | Polycarbonates with a low yellowness index |
GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
CN1167422C (zh) * | 1999-02-10 | 2004-09-22 | 阿斯特拉曾尼卡有限公司 | 用作血管生成抑制剂的喹唑啉衍生物 |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
UY27224A1 (es) * | 2001-03-23 | 2002-10-31 | Bayer Corp | Inhibidores de la rho-quinasa |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
DE60231230D1 (de) * | 2001-11-03 | 2009-04-02 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
GB0128108D0 (en) * | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
WO2003059913A1 (en) * | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
ATE381557T1 (de) * | 2002-01-23 | 2008-01-15 | Bayer Pharmaceuticals Corp | Rho-kinase inhibitoren |
EP1603908B1 (en) * | 2003-03-12 | 2008-06-11 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
-
2002
- 2002-03-22 CA CA2441501A patent/CA2441501C/en not_active Expired - Fee Related
- 2002-03-22 WO PCT/US2002/008660 patent/WO2002076977A2/en active IP Right Grant
- 2002-03-22 EP EP02713884A patent/EP1370552B1/en not_active Expired - Lifetime
- 2002-03-22 TW TW091105577A patent/TWI336328B/zh not_active IP Right Cessation
- 2002-03-22 DK DK02713884T patent/DK1370552T3/da active
- 2002-03-22 PT PT02713884T patent/PT1370552E/pt unknown
- 2002-03-22 PE PE2002000225A patent/PE20020958A1/es not_active Application Discontinuation
- 2002-03-22 AU AU2002245709A patent/AU2002245709A1/en not_active Abandoned
- 2002-03-22 AT AT02713884T patent/ATE353889T1/de active
- 2002-03-22 DE DE60218138T patent/DE60218138T2/de not_active Expired - Lifetime
- 2002-03-22 AR ARP020101070A patent/AR035792A1/es active IP Right Grant
- 2002-03-22 MY MYPI20021019A patent/MY142915A/en unknown
- 2002-03-22 UY UY27225A patent/UY27225A1/es unknown
- 2002-03-22 JP JP2002576235A patent/JP4320705B2/ja not_active Expired - Fee Related
- 2002-03-22 US US10/103,565 patent/US20030087919A1/en not_active Abandoned
- 2002-03-22 MX MXPA03008659A patent/MXPA03008659A/es active IP Right Grant
- 2002-03-22 ES ES02713884T patent/ES2280517T3/es not_active Expired - Lifetime
-
2004
- 2004-06-09 HK HK04104114A patent/HK1061029A1/xx not_active IP Right Cessation
-
2006
- 2006-02-16 US US11/354,978 patent/US20060142314A1/en not_active Abandoned
-
2007
- 2007-04-19 CY CY20071100536T patent/CY1108041T1/el unknown
-
2010
- 2010-03-18 US US12/726,660 patent/US20100249159A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2002245709A1 (en) | 2002-10-08 |
MXPA03008659A (es) | 2005-04-08 |
CY1108041T1 (el) | 2013-09-04 |
US20030087919A1 (en) | 2003-05-08 |
DE60218138D1 (de) | 2007-03-29 |
MY142915A (en) | 2011-01-31 |
CA2441501A1 (en) | 2002-10-03 |
PT1370552E (pt) | 2007-04-30 |
CA2441501C (en) | 2010-09-14 |
UY27225A1 (es) | 2002-10-31 |
TWI336328B (en) | 2011-01-21 |
EP1370552B1 (en) | 2007-02-14 |
ES2280517T3 (es) | 2007-09-16 |
AR035792A1 (es) | 2004-07-14 |
US20100249159A1 (en) | 2010-09-30 |
WO2002076977A2 (en) | 2002-10-03 |
DK1370552T3 (da) | 2007-05-07 |
JP2004528314A (ja) | 2004-09-16 |
ATE353889T1 (de) | 2007-03-15 |
HK1061029A1 (en) | 2004-09-03 |
US20060142314A1 (en) | 2006-06-29 |
WO2002076977A3 (en) | 2002-12-12 |
PE20020958A1 (es) | 2002-11-14 |
EP1370552A2 (en) | 2003-12-17 |
DE60218138T2 (de) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4320705B2 (ja) | Rhoキナーゼ阻害剤 | |
JP4329003B2 (ja) | Rhoキナーゼ阻害剤 | |
JP4505228B2 (ja) | Rho−キナーゼ阻害剤 | |
CN105593224B (zh) | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 | |
CN102803227B (zh) | 吗啉基喹唑啉 | |
ES2427166T3 (es) | Compuesto heterocíclico tricíclico novedoso | |
US7371765B2 (en) | Quinoline derivatives having VEGF inhibiting activity | |
WO2003026666A1 (en) | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors | |
TW201144310A (en) | [5,6] heterocyclic compound | |
KR101921764B1 (ko) | 피라졸로-퀴놀린 | |
JP2016519685A (ja) | Ras/raf/mek/erk経路およびpi3k/akt/pten/mtor経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン | |
JP2004505965A (ja) | 化合物 | |
CN105008353A (zh) | 2-酰基氨基噻唑衍生物或其盐 | |
KR20140097391A (ko) | 암 치료에서 사용되기 위한 모르폴리닐 벤조트리아진 | |
US9353107B2 (en) | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | |
US11897863B2 (en) | Indazole amine derivative, preparation method therefor and medical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081028 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090416 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090519 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090521 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130612 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |